Exosomes for Neurodegenerative Diseases: Diagnosis and Targeted Therapy

Overview

Journal J Neurol

Specialty Neurology

Date 2024 Apr 11

PMID 38605227

Authors

Hui Tao

Bo Gao

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Neurodegenerative diseases are still challenging clinical issues, with no curative interventions available and early, accurate diagnosis remaining difficult. Finding solutions to them is of great importance. In this review, we discuss possible exosomal diagnostic biomarkers and explore current explorations in exosome-targeted therapy for some common neurodegenerative diseases, offering insights into the clinical transformation of exosomes in this field.

Recent Findings: The burgeoning research on exosomes has shed light on their potential applications in disease diagnosis and treatment. As a type of extracellular vesicles, exosomes are capable of crossing the blood - brain barrier and exist in various body fluids, whose components can reflect pathophysiological changes in the brain. In addition, they can deliver specific drugs to brain tissue, and even possess certain therapeutic effects themselves. And the recent advancements in engineering modification technology have further enabled exosomes to selectively target specific sites, facilitating the possibility of targeted therapy for neurodegenerative diseases. The unique properties of exosomes give them great potential in the diagnosis and treatment of neurodegenerative diseases, and provide novel ideas for dealing with such diseases.

Citing Articles

Skeletal myotubes expressing ALS mutant SOD1 induce pathogenic changes, impair mitochondrial axonal transport, and trigger motoneuron death.

Martinez P, Silva M, Abarzua S, Tevy M, Jaimovich E, Constantine-Paton M Mol Med. 2024; 30(1):185.

PMID: 39455931 PMC: 11505737. DOI: 10.1186/s10020-024-00942-4.

References

Erkkinen M, Kim M, Geschwind M . Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 10(4). PMC: 5880171. DOI: 10.1101/cshperspect.a033118. View

Wright B, Lai J, Sinclair A . Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol. 2012; 259(8):1530-45. DOI: 10.1007/s00415-012-6413-x. View

Dong X . Current Strategies for Brain Drug Delivery. Theranostics. 2018; 8(6):1481-1493. PMC: 5858162. DOI: 10.7150/thno.21254. View

Thomsen M, Humle N, Hede E, Moos T, Burkhart A, Thomsen L . The blood-brain barrier studied in vitro across species. PLoS One. 2021; 16(3):e0236770. PMC: 7954348. DOI: 10.1371/journal.pone.0236770. View

Gray S, Woodard K, Samulski R . Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv. 2012; 1(4):517-34. PMC: 4509525. DOI: 10.4155/tde.10.50. View

Vagner T, Dvorzhak A, Wojtowicz A, Harms C, Grantyn R . Systemic application of AAV vectors targeting GFAP-expressing astrocytes in Z-Q175-KI Huntington's disease mice. Mol Cell Neurosci. 2016; 77:76-86. DOI: 10.1016/j.mcn.2016.10.007. View

Wohlfart S, Gelperina S, Kreuter J . Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2011; 161(2):264-73. DOI: 10.1016/j.jconrel.2011.08.017. View

Kreuter J . Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). J Microencapsul. 2012; 30(1):49-54. DOI: 10.3109/02652048.2012.692491. View

Saraiva C, Praca C, Ferreira R, Santos T, Ferreira L, Bernardino L . Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016; 235:34-47. DOI: 10.1016/j.jconrel.2016.05.044. View

10.

Pinheiro R, Coutinho A, Pinheiro M, Neves A . Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?. Int J Mol Sci. 2021; 22(21). PMC: 8584083. DOI: 10.3390/ijms222111654. View

11.

Ogawa K, Kato N, Yoshida M, Hiu T, Matsuo T, Mizukami S . Focused ultrasound/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain. J Control Release. 2022; 348:34-41. DOI: 10.1016/j.jconrel.2022.05.042. View

12.

Chu C, Jablonska A, Lesniak W, Thomas A, Lan X, Linville R . Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex. J Control Release. 2019; 317:312-321. DOI: 10.1016/j.jconrel.2019.11.019. View

13.

Bhattamisra S, Shak A, Xi L, Safian N, Choudhury H, Meng Lim W . Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease. Int J Pharm. 2020; 579:119148. DOI: 10.1016/j.ijpharm.2020.119148. View

14.

Harding C, Heuser J, Stahl P . Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983; 97(2):329-39. PMC: 2112509. DOI: 10.1083/jcb.97.2.329. View

15.

Kalluri R, LeBleu V . The biology function and biomedical applications of exosomes. Science. 2020; 367(6478). PMC: 7717626. DOI: 10.1126/science.aau6977. View

16.

Rastogi S, Sharma V, Bharti P, Rani K, Modi G, Nikolajeff F . The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis. Int J Mol Sci. 2021; 22(1). PMC: 7795439. DOI: 10.3390/ijms22010440. View

17.

Fan Y, Chen Z, Zhang M . Role of exosomes in the pathogenesis, diagnosis, and treatment of central nervous system diseases. J Transl Med. 2022; 20(1):291. PMC: 9235237. DOI: 10.1186/s12967-022-03493-6. View

18.

Doyle L, Wang M . Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells. 2019; 8(7). PMC: 6678302. DOI: 10.3390/cells8070727. View

19.

Fuhrmann G, Herrmann I, Stevens M . Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. Nano Today. 2017; 10(3):397-409. PMC: 5409525. DOI: 10.1016/j.nantod.2015.04.004. View

20.

Rehman F, Liu Y, Zheng M, Shi B . Exosomes based strategies for brain drug delivery. Biomaterials. 2022; 293:121949. DOI: 10.1016/j.biomaterials.2022.121949. View